NCT01604746已完成3 期
Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,146
- 试验地点
- 26
- 主要终点
- Incidence of SAEs and AESI, such as arthritis, Guillain Barré Syndrome (GBS), encephalitis, convulsions, Bell´s palsy, neuritis, vasculitis, demyelinating disorders (ADEM and myelitis) and vaccination failure
研究概览
简要总结
The purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who participated in precursor Study 880801 and meet all of the following criteria:
- •Subject received 3 RRV vaccinations in Study 880801
- •Subject has completed Visit 6 in Study 880801
- •Subject and, if applicable, subject´s parent(s)/legal guardian(s), understand the nature of the study and its procedures, agree to its provisions and provide written informed consent prior to study entry
- •Subject provides written assent according to his/her age, if applicable
排除标准
- •Subject has participated in another clinical study other than Study 880801 involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
结局指标
主要结局
Incidence of SAEs and AESI, such as arthritis, Guillain Barré Syndrome (GBS), encephalitis, convulsions, Bell´s palsy, neuritis, vasculitis, demyelinating disorders (ADEM and myelitis) and vaccination failure
时间窗: 12 months after the third vaccination administered in precursor study 880801
SAE = Serious adverse event, AESI = Adverse event of special interest
次要结局
未报告次要终点
研究者
研究点 (26)
Loading locations...
相似试验
已完成
3 期
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JPRheumatoid ArthritisNCT00144547Chugai Pharmaceutical241
已完成
3 期
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JPRheumatoid ArthritisNCT00144534Chugai Pharmaceutical115
已完成
3 期
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JPRheumatoid ArthritisNCT00144586Chugai Pharmaceutical42
已完成
2 期
A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac AmyloidosisTTR-mediated AmyloidosisNCT02292186Alnylam Pharmaceuticals25
进行中（未招募）
3 期
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary DiseaseNCT05878769Hoffmann-La Roche2,000